Bevacizumab in recurrence or progress of high-grade gliomas

Th e prognosis for patients suff ering from malignant gliomas remains dismal. We report on 10 patients with recurring or progressing high-grade gliomas who were treated at our institution with Bevacizumab alone or in combination with cytostatic drugs over the last 2 years. Th e survival time from the start of the VEGFR antibody therapy on average was 18 weeks (10-30 weeks) and after Avastin was discontinued patients lived an average of 7 weeks (1-14 weeks). Th e above results support further studies of this very promising drug in the form of randomized studies of malignant glioma. In the primary therapy concept and in the case of recurrence the best combination Bevacizumab with cytostatics, radiation therapy or other targeted therapies have to be clarifi ed.